Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib, Pembrolizumab, and Fulvestrant in ER+/HER2- Metastatic Breast Cancer
NCT06110793Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2023
- Primary completion
- Nov 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and pembrolizumab in breast cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Adverse Events and Dose-Limiting Toxicities at 1 year. Started Dec 2023; status: active, not recruiting.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06110793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06110793.